UK collaboration for magnetotherapy technology:
This article was originally published in Clinica
Executive Summary
Biotech firm Celltech has formed a UK collaboration to develop a magnetic-guided antibody therapy for treating cancer. The project will initially run for two years and will evaluate the use of Celltech's targeted antibody therapy in treating tumour cells with magnetically controlled nanoparticles. Researchers from the University of Durham will run the trials and will also be responsible for producing and coating the nanoparticles. Oxford Instruments Molecular Biotools will develop the external magnetic technology used to mediate the magnetically attached antibodies. Professor Mike Eaton, head of Celltech Antibody Chemistry, told Clinica that the antibody-targeted magnetotherapy could be available in clinics within the next five years. However, he declined to disclose any information about the nanoparticles used in the trials.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.